Axon Enterprise, Inc.
AXON scores 46.3 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (0.0 points) applied. AXON's rank of #725 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
No risk factors identified.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| AXON | 46.3 | 135.1 | 33.4% | 18.1% | $34.1B |
| FER | 84.1 | 12.2 | 7.4% | 35.3% | $53.6B |
| NDSN | 77.2 | 35.1 | 3.8% | 17.4% | $16.0B |
| OMAB | 76.4 | 20.1 | 4.3% | 32.7% | $6.0B |
| ODFL | 76.3 | 39.8 | -0.9% | 20.4% | $42.2B |
| FAST | 73.1 | 42.6 | 8.7% | 15.3% | $52.8B |
| CSX | 71.5 | 26.5 | -3.1% | 20.5% | $79.2B |
| WWD | 71.3 | 47.8 | 7.3% | 12.4% | $23.1B |
| LECO | 71.3 | 31.5 | -4.4% | 11.6% | $15.5B |
| PCAR | 71.0 | 28.2 | -4.2% | 12.4% | $65.2B |
| CTAS | 70.8 | 41.9 | 7.7% | 17.5% | $80.2B |
| RYAAY | 69.9 | 13.0 | 3.8% | 11.6% | $35.5B |
| CPRT | 69.5 | 23.0 | 9.7% | 33.4% | $36.2B |
| FELE | 69.3 | 35.5 | -2.1% | 8.9% | $4.4B |
| NSSC | 68.9 | 34.5 | -3.8% | 24.7% | $1.6B |
| AEIS | 68.0 | 81.2 | 21.4% | 8.3% | $12.5B |
| Sector Average | 45.8 | 49.9 | 19.0% | -48.2% | โ |
Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness, including streamlined investigative workflows. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.
Stock is in a downtrend below the 200-day moving average. Price is below both the 50-day and 200-day SMAs, indicating sustained selling pressure.
Stage 4 downtrend โ price is below both SMA50 and SMA200 with a declining 200-day average. Capital preservation takes priority. Do not buy into a downtrend.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $797M | $711M | $669M | $604M |
| Gross Profit | $461M | $427M | $404M | $366M |
| Operating Income | $10M | $-2M | $1M | $-8M |
| Net Income | $3M | $-2M | $36M | $88M |
| EPS (Diluted) | $0.03 | $-0.03 | $0.44 | $1.08 |
| Gross Margin | 57.9% | 60.1% | 60.4% | 60.6% |
| Operating Margin | 1.3% | -0.3% | 0.2% | -1.3% |
| Net Margin | 0.4% | -0.3% | 5.4% | 14.6% |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.